Metacrine Reports Second-Quarter 2022 Results
On August 9, 2022, Metacrine reported its second-quarter 2022 financial results, showing a significant reduction in expenses. Cash and equivalents reached $55.5 million, expected to fund operations through 2023. R&D expenses decreased to $2.3 million from $11.4 million year-over-year, while G&A expenses dropped to $3.4 million. The net loss narrowed to $6.3 million from $15.6 million. The company is exploring strategic alternatives, including potential mergers or partnerships, aiming to enhance shareholder value.
- Cash balance sufficient to fund operations through 2023.
- Significant decrease in R&D expenses from $11.4 million to $2.3 million.
- G&A expenses reduced from $4.0 million to $3.4 million.
- Improvement in net loss from $15.6 million to $6.3 million.
- None.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its second-quarter 2022 financial results.
“We have made meaningful progress during the quarter in evaluating strategic alternatives designed to maximize stockholder value,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. Potential strategic alternatives to be explored and evaluated may include a merger, sale, or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of our programs.
Second-Quarter 2022 Financial Results
- Cash Balance - Cash, cash equivalents and short-term investments were
$55.5 million as of June 30, 2022. Metacrine believes it has sufficient capital to fund its current operating plan through 2023. - R&D Expenses - Research and development expenses were
$2.3 million for the three months ended June 30, 2022, as compared to$11.4 million for the prior-year period. The decrease was primarily driven by lower clinical development costs related to the MET409 and MET642 programs and lower employee-related costs. - G&A Expenses - General and administrative expenses were
$3.4 million for the three months ended June 30, 2022, as compared to$4.0 million for the prior-year period. The decrease was attributable to lower employee-related costs and expenses associated with operating as a publicly traded company. - Net Loss - Net loss was
$6.3 million for the three months ended June 30, 2022, as compared to$15.6 million for prior-year period.
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. To learn more, visit www.metacrine.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements about the sufficiency of Metacrine’s capital to fund its current operating plan through 2023 and statements about Metacrine’s evaluation of strategic alternatives. Words such as “may,” “potential,” “believes” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Metacrine’s expectations and assumptions that may never materialize or prove to be incorrect. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks related to Metacrine’s ability to identify and consummate strategic alternatives that yield additional value for stockholders; the timing, benefits and outcome of Metacrine’s strategic alternatives review process, including the determination of whether or not to pursue or consummate any strategic alternative; the structure, terms and specific risks and uncertainties associated with any potential strategic transaction; potential disruptions in Metacrine’s business and the stock price as a result of the evaluation of strategic alternatives or the public announcement thereof and any decision or transaction resulting from such evaluation; potential delays in initiating, enrolling or completing any clinical trials; competition from third parties; and Metacrine’s ability to obtain, maintain and protect its intellectual property. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Metacrine’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2022, and in Metacrine’s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as required by law, Metacrine assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Investor & Media Contact
Investor Relations
Metacrine, Inc.
investors@metacrine.com
| Metacrine, Inc. | ||||||||||||||||
| Unaudited Condensed Consolidated Statements of Operations | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 2,309 | $ | 11,368 | $ | 8,989 | $ | 22,225 | ||||||||
| General and administrative | 3,412 | 3,992 | 8,894 | 7,688 | ||||||||||||
| Restructuring charges | 44 | — | 902 | — | ||||||||||||
| Gain from lease termination and asset sale | — | — | (508 | ) | — | |||||||||||
| Total operating expenses | 5,765 | 15,360 | 18,277 | 29,913 | ||||||||||||
| Loss from operations | (5,765 | ) | (15,360 | ) | (18,277 | ) | (29,913 | ) | ||||||||
| Total other income (expense) | (497 | ) | (225 | ) | (865 | ) | (440 | ) | ||||||||
| Net loss | $ | (6,262 | ) | $ | (15,585 | ) | $ | (19,142 | ) | $ | (30,353 | ) | ||||
| Metacrine, Inc. | ||||||||
| Unaudited Condensed Consolidated Balance Sheets | ||||||||
| (In thousands) | ||||||||
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash, cash equivalents, and short-term investments | $ | 55,530 | $ | 76,427 | ||||
| Prepaid expenses and other current assets | 3,611 | 2,313 | ||||||
| Total current assets | 59,141 | 78,740 | ||||||
| Property and equipment, net | — | 347 | ||||||
| Operating lease right-of-use asset | — | 902 | ||||||
| Total assets | $ | 59,141 | $ | 79,989 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 503 | $ | 368 | ||||
| Accrued and other current liabilities | 2,150 | 7,392 | ||||||
| Total current liabilities | 2,653 | 7,760 | ||||||
| Long-term debt, net of debt discount | 13,616 | 13,303 | ||||||
| Other long-term liabilities | 1,388 | 1,571 | ||||||
| Stockholders’ equity | 41,484 | 57,355 | ||||||
| Total liabilities and stockholders’ equity | $ | 59,141 | $ | 79,989 | ||||
FAQ
What were Metacrine's financial results for Q2 2022?
How much cash does Metacrine have as of June 30, 2022?
What strategic alternatives is Metacrine considering?
What were the R&D expenses for Metacrine in Q2 2022?
What are the general and administrative expenses for Metacrine in Q2 2022?
